BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu L, Liu Z, Dong R, Wang X, Zhang M, Guo X, Yu N, Zeng A. MicroRNA-3662 targets ZEB1 and attenuates the invasion of the highly aggressive melanoma cell line A375. Cancer Manag Res 2019;11:5845-56. [PMID: 31388313 DOI: 10.2147/CMAR.S200540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Cai S, Xiong Q, Weng D, Wang Q, Ma Z. PIK3R2 predicts poor outcomes for patients with melanoma and contributes to the malignant progression via PI3K/AKT/NF-κB axis. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-03036-x] [Reference Citation Analysis]
2 Yi B, Wang S, Wang X, Liu Z, Zhang C, Li M, Gao S, Wei S, Bae S, Stringer-Reasor E, Wang L, Liu R. CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer. Oncogene 2021. [PMID: 34728806 DOI: 10.1038/s41388-021-02089-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 He Z, Xin Z, Peng Y, Zhao H, Fang X. Construction of competing endogenous RNA interaction network as prognostic markers in metastatic melanoma. PeerJ 2021;9:e12143. [PMID: 34616613 DOI: 10.7717/peerj.12143] [Reference Citation Analysis]
4 Jiang Q, Ma Y, Han J, Chu J, Ma X, Shen L, Liu B, Li BA, Hou J, Bi Q. MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor. Front Oncol 2021;11:715193. [PMID: 34249768 DOI: 10.3389/fonc.2021.715193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
5 Xu Y, Guo B, Liu X, Tao K. miR-34a inhibits melanoma growth by targeting ZEB1. Aging (Albany NY) 2021;13:15538-47. [PMID: 34102608 DOI: 10.18632/aging.203114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ghafouri-Fard S, Gholipour M, Taheri M. MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets. Front Oncol 2021;11:608987. [PMID: 33968718 DOI: 10.3389/fonc.2021.608987] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
7 Chen B, Sun D, Qin X, Gao XH. Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis. Invest New Drugs 2021;39:928-48. [PMID: 33501609 DOI: 10.1007/s10637-021-01072-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ashrafizadeh M, Ang HL, Moghadam ER, Mohammadi S, Zarrin V, Hushmandi K, Samarghandian S, Zarrabi A, Najafi M, Mohammadinejad R, Kumar AP. MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy. Biomolecules 2020;10:E1040. [PMID: 32664703 DOI: 10.3390/biom10071040] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
9 Donato G, Presta I, Arcidiacono B, Vismara MFM, Donato A, Garo NC, Malara N. Innate and Adaptive Immunity Linked to Recognition of Antigens Shared by Neural Crest-Derived Tumors. Cancers (Basel) 2020;12:E840. [PMID: 32244473 DOI: 10.3390/cancers12040840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]